Leon Kircik

Featured in: Favicon

jamanetwork.com Favicon

hcplive.com Favicon

unirioja.es Favicon

hmpgloballearningnetwork.com Favicon

tmc.edu

futuremedicine.com Favicon

jaad.org

dermatologytimes.com Favicon

practicaldermatology.com Favicon

jofskin.org + 2 more

Articles

Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD

2 weeks ago | patientcareonline.com | Leon Kircik |Grace Halsey

Janus kinase (JAK) inhibitors provide rapid efficacy in the management of atopic dermatitis (AD) but present safety concerns for some heath care professionals because of the FDA black box warning across the class, a high-level precaution required following clinical trials of tofacitinib in rheumatoid arthritis.1 In an interview with Patient Care at Revolutionizing Atopic Dermatitis 2025 in Nashville, Tennessee, June 6-7, Leon Kircik, MD, clarified misconceptions around the boxed warning,...
Q&A: Reframing JAK Inhibitor Safety and Flexibility in AD With Leon Kircik, MD

3 weeks ago | dermatologytimes.com | Leon Kircik |Kaitlyn Bader

In a recent interview at the 2025 Revolutionizing Atopic Dermatitis Conference (RAD) in Nashville, Tennessee, Leon Kircik, MD, discussed key takeaways for clinicians from his session, “Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management." Kircik is the founder and medical director of DermResearch and Physicians Skin Care, both in Louisville, as well as clinical professor of dermatology at Indiana University Medical Center in Indianapolis and at the Icahn School of Medicine in...
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials

Jun 5, 2024 | digitalcommons.library.tmc.edu | Mark Lebwohl |Leon Kircik |Angela Moore |Linda Gold

IMPORTANCE: Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of patients with psoriasis. OBJECTIVE: To evaluate the efficacy of roflumilast cream, 0.3%, applied once daily for 8 weeks in 2 trials of patients with plaque psoriasis.
Expert Insights into Emerging Biologic Psoriasis Treatments

Jan 9, 2024 | dermatologytimes.com | Leon Kircik |George Han

January 9, 2024George Han, MD, discusses the latest biologic agents for plaque psoriasis, addressing the balance between efficacy and speed of response. Together with Dr. Leon Kircik, they emphasize the significance of comprehensive data for physician confidence and delve into the clinical utilization of these treatments, stressing the importance of baseline laboratory measurements for all prescribed patients.
Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Nov 13, 2023 | jofskin.org | Diamant Thaçi |Mark Lebwohl |Richard Warren |Leon Kircik

1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736. 2. Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb; September 2022. 3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023. 4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022. 5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022. 6. Sotyktu [product monograph].
Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab

Nov 13, 2023 | jofskin.org | Leon Kircik |Melinda Gooderham

Main Article Content Keywords Lebrikizumab, atopic dermatitis, itch, skin, improvement References 1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547. 2.
Patient- and Clinician-Reported Outcomes of Tirbanibulin 1% in the Treatment of Actinic Keratosis on the Face and Scalp (PROAK Study)

Nov 13, 2023 | jofskin.org | Todd E. Schlesinger |April Armstrong |Vishal Patel |Leon Kircik

Introduction: Actinic Keratosis (AK) has been shown to negatively affect emotional and social functioning and skin-related quality of life [1].
Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne | SKIN The Journal of Cutaneous Medicine

Jul 16, 2023 | jofskin.org | Linda Gold |Leon Kircik |William Werschler |Hilary E. Baldwin

Main Article Content Keywords Pediatric, Adult, Acne, Male, Female, Retinoid, BPO, Adapalene, Clindamycin, Antibiotic, Combination Abstract Introduction: IDP-126 (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) polymeric mesh gel is the first triple-combination, fixed-dose topical acne treatment in development. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability, in a phase 2 and two phase 3 studies of participants with...
Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants | SKIN The Journal of Cutaneous Medicine

Jul 16, 2023 | jofskin.org | Zoe D. Draelos |Emil Tanghetti |Linda Gold |Leon Kircik

Main Article Content Keywords Tolerability, Irritation, CIPT, RIPT, Retinoid, BPO, Adapalene, Clindamycin, Antiobiotic, Combination Abstract Introduction: IDP-126 polymeric mesh gel (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) is the first triple-combination, fixed-dose topical acne product in development and it addresses major acne pathophysiological processes. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability in...

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Leon Kircik

Articles

Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD

Q&A: Reframing JAK Inhibitor Safety and Flexibility in AD With Leon Kircik, MD

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials

Expert Insights into Emerging Biologic Psoriasis Treatments

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab

Patient- and Clinician-Reported Outcomes of Tirbanibulin 1% in the Treatment of Actinic Keratosis on the Face and Scalp (PROAK Study)

Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne | SKIN The Journal of Cutaneous Medicine

Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants | SKIN The Journal of Cutaneous Medicine

Contact details

Emails

Socials & Sites